Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1594)	12/26/2015 12:40:45 PM
From: eico20	Read Replies (1) \| Respond to of 2026

excellent input MI, I stopped reading the reports after seeing how dismal Vitaros sales are, obviously there are obstacles to sales, cold temp is one of those obstacles, and hopefully world wide distribution of the RTD in the next few years will provide decent income to cover operating expenses and RTD Vitaros milestones will help with clinical trial costs. Predicting the clinical success with Fis. I think will have much more reward than with Vitaros, since Fis. really is a blockbuster if successful, especially now that Endroxal is very delayed if not knocked out. It will only be a PH2 result but I agree they will borrow around the time of Fis. results in Q1 16. I agree Pascoe is holding out on borrowing around good results on the Fis. and maybe some diluting for better Vitaros sales soon after. In regards to Fis., blocking estrogen and raising testosterone has had mixed results on sexual symptoms, APRI has some experience with it in the PH2A Fis. trial, so they must have some confidence in a higher dose on less severe ED patients, let's see if they can prove significance with ED as the primary endpoint, cause it's doubtful with libido. Barb T. told me the FDA wants nothing to do with weight loss type endpoints and estrogen blockers, so I hope the FDA is not forcing Apri down the wrong path when it comes to 2nd HG. A recent study shows benefit of insulin sensitivity pointing to metabolic disorder as an underlying cause. http://www.diabetesincontrol.com/testosterone-increasing-insulin-sensitivity/ Testosterone Increasing Insulin Sensitivity A known link between low testosterone levels and decreased insulin sensitivity could lead to a treatment for men with type 2. New study shows that increasing testosterone levels can help male patients with type 2 diabetes increase their response to insulin. In individuals with insulin resistance, their body produces insulin, but does not effectively utilize their insulin. Insulin resistance leads to a build up of glucose in the blood rather than being absorbed by the cells. Ultimately, insulin resistance can lead to diabetes as well as other health issues such as heart disease.